Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
IPO Year: 2020
Exchange: NASDAQ
Website: harmonybiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $61.00 | Outperform | Oppenheimer |
| 2/11/2025 | $55.00 | Buy | Deutsche Bank |
| 12/17/2024 | $75.00 | Buy | H.C. Wainwright |
| 10/10/2024 | Outperform | Raymond James | |
| 9/10/2024 | $56.00 | Buy | UBS |
| 6/21/2024 | $48.00 | Buy | Citigroup |
| 1/2/2024 | $30.00 | Neutral → Underperform | BofA Securities |
| 9/25/2023 | $40.00 → $31.00 | Neutral → Sell | Goldman |
| 9/7/2023 | $59.00 | Buy | Berenberg |
| 4/20/2023 | $35.00 | Neutral | BofA Securities |